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Abstract
Several studies have demonstrated that cytokine-mediated noncytopathic suppression of hepatitis B virus (HBV) replication
may provide an alternative therapeutic strategy for the treatment of chronic hepatitis B infection. In our previous study, we
showed that transforming growth factor-beta1 (TGF-b1) could effectively suppress HBV replication at physiological
concentrations. Here, we provide more evidence that TGF-b1 specifically diminishes HBV core promoter activity, which
subsequently results in a reduction in the level of viral pregenomic RNA (pgRNA), core protein (HBc), nucleocapsid, and
consequently suppresses HBV replication. The hepatocyte nuclear factor 4alpha (HNF-4a) binding element(s) within the HBV
core promoter region was characterized to be responsive for the inhibitory effect of TGF-b1 on HBV regulation.
Furthermore, we found that TGF-b1 treatment significantly repressed HNF-4a expression at both mRNA and protein levels.
We demonstrated that RNAi-mediated depletion of HNF-4a was sufficient to reduce HBc synthesis as TGF-b1 did. Prevention
of HNF-4a degradation by treating with proteasome inhibitor MG132 also prevented the inhibitory effect of TGF-b1. Finally,
we confirmed that HBV replication could be rescued by ectopic expression of HNF-4a in TGF-b1-treated cells. Our data
clarify the mechanism by which TGF-b1 suppresses HBV replication, primarily through modulating the expression of HNF-4a
gene.
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Introduction
Chronic infection with hepatitis B virus (HBV) is a major
worldwide issue in public health and is one of the best known high-
risk factors for cirrhosis and hepatocellular carcinoma (HCC) [1,2].
The molecular mechanisms of HBV replication and the regulatory
elements within the HBV genome have been extensively studied
[3,4]. Following virus entry into hepatocytes, the circular partially
double-stranded viral genome is converted into a covalently closed
circular DNA(cccDNA)inthe nucleus. ThiscccDNAthen becomes
the template for transcription of pregenomic RNA (pgRNA) and
other subgenomic messenger RNAs (mRNAs). The viral pgRNA
not only serves as mRNA for the synthesis of the HBV core protein
(HBc) and polymerase butalsoassembles with the HBcand the viral
polymerase to form nucleocapsids [3]. Thus, the expression level of
pgRNA is considered to play a central role in controlling the level of
HBV replication [5].
The transcription of pgRNA is regulated by the core promoter,
which consists of the basal core promoter and the core upstream
regulatory sequence (CURS, also referred as enhancer II) [6]. The
CURS contains several cis-acting elements and the binding of
different transcription factors on this region positively or negatively
modulates the downstream core promoter activity [4,7]. Several
transcription factors, including specific protein 1 (SP1), chicken
ovalbumin upstream promoter transcription factor 1 (COUP-TF1),
hepatocyte nuclear factor 3 (HNF-3), HNF-4a, human testicular
receptor 2 (TR2), peroxisome proliferators activated receptor alpha
(PPARa), and retinoid X receptor alpha (RXRa) have been shown
to interact with the CURS region of the core promoter [8,9,10].
Among these transcription factors, HNF-4a plays an important role
in controlling the expression of viral pgRNA. The binding of HNF-
4a to the regulatory element of the core promoter has been shown
to generate the fundamental complex required for pgRNA synthesis
[5,11]. Moreover, HNF-4a is reported to differentially regulate
transcription of pgRNA and pre-C mRNA. Overexpression of
HNF-4a alone leads to at least an eight-fold increase in pgRNA
synthesis but only a two-fold increase in pre-C mRNA [12].
Moreover, HNF-4a plays a transcriptional hierarchywhich controls
hepatic genes expression, hepatocyte differentiation, and even liver
morphogenesis [13,14,15,16].
Transforming growth factor-beta 1 (TGF-b1) is a pleiotropic
cytokine that is implicated in multiple biological functions in the
liver, including the delay of hepatocyte proliferation, the
modulation of hepatocyte growth factor signaling, and the
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significantly increased after liver injury, during which hepatic
stellate cells (HSCs) are considered to be the major source of
secreted TGF-b1 [18]. Moreover, it has been reported that HBV
replication induces hepatocytes to secret TGF-b [19]. Clinical
investigation also revealed that plasma TGF-b1 is significantly
elevated in patients with chronic hepatitis (CHB), cirrhosis, and
HCC [20,21,22]. In our previous study, we have shown that TGF-
b1 also functions as an antiviral cytokine which could efficiently
inhibit HBV replication in HBV-producing HepG2 cells [23].
However, the precise molecular mechanism by which TGF-b1
exerts its antiviral effect is not well characterized.
Figure 1. TGF-b1 represses viral replication in HBV expressing cells. 1.3ES2 cells were treated with or without TGF-b1 for 6 days. (A) Total
DNA was extracted followed by HindIII digestion. The viral replicative intermediates were examined by Southern blot analysis using an HBV-specific
probe. The intensity of the integrated HBV genome was used as internal control for the equal amount of sample loading. Bands corresponding to the
integrated genome (integrated), the relaxed circular double-stranded DNA (RC), the replicative intermediates are indicated individually. (B) Total RNA
was extracted, and the expression of viral transcripts were examined by Northern blot analysis using HBV-specific probe. Expression of GAPDH was
used as an internal control. (C) The amount of pgRNA and pre-C transcripts was analyzed by primer extension analysis. The schematic illustration
shows the relative position of the HBV-specific primers used for primer extension analysis. (D) The cell lysate was harvested, and the expression level
of HBc was determined by Western blot analysis. HBV nucleocapsids and the embedded viral gnome were detected by using particle blot analysis.
Expression of actin was used as an internal control.
doi:10.1371/journal.pone.0030360.g001
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mechanism of HBV inhibition mediated by TGF-b1. We demon-
strated that TGF-b1 represses the expression of HNF-4a, which
reduces the level of HBV pgRNA and consequently inhibits HBV
replication. Our data suggests that HNF-4a is the key responsive
regulator in TGF-b1-mediated HBV suppression. The detail
mechanism by which TGF-b1 inhibits HBV replication and the
role of HNF-4a in cytokine-mediated viral clearance are discussed.
Results
TGF-b1 represses HBV replication in the stably HBV-
expressing HepG2 cells
To elucidate the effects of TGF-b1 on HBV replication, 1.3ES2
cells were treated with or without TGF-b1 for 6 days, and the
inhibitory effects of TGF-b1 on HBV replication were examined.
As mentioned in our previous study [23], the expression levels of
viral relaxed circular double-stranded DNA (RC) and replicative
intermediates were substantially repressed in the presence of TGF-
b1 (Fig. 1A). Meanwhile, the synthesis of viral transcripts,
especially the 3.5 kb transcripts of HBV, was efficiently repressed
by TGF-b1 treatment (Fig. 1B). To clarify which species of HBV
3.5 kb transcripts (either pre-C mRNA or pgRNA) was reduced by
TGF-b1 treatment, we performed primer extension analysis to
detect the amounts of pre-C mRNA and pgRNA in the presence
of TGF-b1. An HBV-specific primer was used for the primer
extension assay, which was designed to generate a 237-nucleotide
fragment from pgRNA and a 267-nucleotide fragment from pre-C
mRNA. By densitometry analysis, our data revealed that
treatment with 10 ng/ml of TGF-b1 significantly inhibited the
level of pgRNA by 81% but only diminished pre-C mRNA by
16% (Fig. 1C). The differential reduction of pgRNA and pre-C
mRNA by TGF-b1 treatment was consistent with our previous
finding [23]. The preferential reduction of HBV pgRNA by TGF-
b1 treatment suggested that the expression level of HBc should be
specifically repressed. Indeed, we found by Western blot analysis
that TGF-b1 treatment dramatically decreased the level of HBc
(Fig. 1D). On the other hand, the expression level of HBV e
antigen (HBe), which was translated from pre-C transcripts, was
not profoundly influenced under TGF-b1 treatment ([23] and data
not shown). Furthermore, Particle blot analysis demonstrated that
the formation of nucleocapsids was significantly repressed by
TGF-b1 treatment, as shown by the disappearance of both viral
capsids and encapsidated nucleic acids after TGF-b1 treatment
(Fig. 1D). These results indicated that TGF-b1 treatment
specifically reduced the expression of viral pgRNA, which
subsequently decreased the level of HBc, prevented the assembly
of intracellular nucleocapsids and finally blocked HBV replication.
We therefore further clarified the mechanism by which TGF-b1
exerts its inhibitory effect on HBV replication.
The HNF-4a binding sites are the responsive elements for
the repression of HBV core promoter activity by TGF-b1
Previousstudieshave identifiedseveralregulatoryelementswhich
are located within the enhancer I/X promoter and core promoter
region contribute to the transcriptional regulation of pgRNA
[4,7,24,25]. To explore the responsive element involved in the
TGF-b1-mediated reduction of HBV pgRNA, HepG2 cells were
transfected with luciferase reporters, which contains HBV enhancer
I/X promoter and core promoter, and the promoter activities were
measured in the presence or absence of TGF-b1. We found that
TGF-b1 specifically and substantially inhibited HBV core promoter
by 52% (Fig. 2A, left panel, CP). However, TGF-b1 only slightly
modulated enhancer I/X promoter. (Fig. 2A, right panel, EnI/X).
To further investigate the responsive element involved in the TGF-
b1-mediated reduction of HBV pgRNA, HepG2 cells were
transfected with a series of luciferase reporters, which contains
intact HBV core promoter (Fig. 2B, upper panel, CP) or truncated
HBV core promoters (Fig. 2B, upper panel, CPD1, CPD2 and
CPD3), and their core promoter activities were examined in the
presence or absence of TGF-b1. The reporter assay revealed that
the intact HBV core promoter activity was significantly reduced by
53% after TGF-b1 treatment (Fig. 2B, lower panel, CP).
Meanwhile, TGF-b1 showed similar repressive ability over the
reporter CPD1, with 58% of the promoter activity corresponding to
their TGF-b1 untreated control cells (Fig. 2B, lower panel, CPD1).
Reporter with further deletion from the 59-end of HBV core
promoter showed severe reduction of the core reporter activity, of
which the repressive abilities mediated by TGF-b1 treatment was
significantly rescued as compared to its own mock control (Fig. 2B,
lower panel, CPD2). This implies that the predominant element
responsible for the inhibitory effect of TGF-b1 is likely to be
embedded within the 59-end of HBV core promoter, probably in
the region between 1656 and 1675. Since the binding element of
HNF-4a, a critical transcription factor for HBV pgRNA biosyn-
thesis [10,12], is located within this region, we proposed that HNF-
4a might serve as the responsive factor in the suppression of HBV
triggered by TGF-b1. To further confirm this speculation, several
reporter plasmids with point mutations inside the two HNF-4a-
binding elements (HNF4BEs), which have been reported to
specifically disrupt the binding of HNF-4a to HBV core promoter
[12,26],wereconstructed(Fig.2C,upperpanel).Althoughthe point
mutation within either 59-o r3 9-HNF4BE (NEm or Npm)
diminished HBV core promoter activity, the NEm and Npm
mutant showed only moderate repression (68% and 66% of control
cells, respectively) in their promoter activities after TGF-b1
treatment (Fig.2C, lower panel). A reporter with double mutations
in both HNF4BEs (NEpm) showed complete resistance to the
inhibitory effect of TGF-b1, even though the promoter activity of
NEpm mutant was much weaker than that of wild-type core
promoter (Fig. 2C, lower panel, NEpm). Our results suggested that
intact HNF4BEs are essential for the down-regulation of HBV core
promoter activity by TGF-b1 treatment.
Intact HNF-4a binding sites within the HBV core
promoter are essential for the antiviral effect of TGF-b1
Next, we examined whether the intact HNF4BEs within the
HBV core promoter are essential for the inhibitory effect of TGF-
b1 on HBV replication. To elucidate the role of HNF4BEs in
TGF-b1-mediated HBV repression, an HNF4BE doubly-mutated
HBV-producing cell line, 1.3NEpm, was established (Fig. 3A). As
mentioned above, TGF-b1 treatment resulted in a substantial
reduction of HBc expression in wild-type 1.3ES2 cells (Fig. 3B,
1.3ES2). Moreover, our data demonstrated that TGF-b1 treat-
ment obviously repressed HBV replication as shown by the
reduction of RC and viral replicative intermediates (Fig. 3C,
1.3ES2). With mutations in the HNF4BEs of HBV core promoter,
1.3NEpm cells produced relatively fewer amounts of HBc than
wild-type 1.3ES2 cells did (Fig. 3B, 1.3NEpm). Interestingly, we
found that TGF-b1 treatment failed to decrease the expression of
HBc in 1.3NEpm cells as demonstrated by its relative low but
consistently expressed HBc after TGF-b1 treatment (Fig. 3B,
1.3NEpm). Coincidently, the replication level of HBV in
1.3NEpm cells was relative less than that in 1.3ES2 cells.
Meanwhile, we observed that TGF-b1 treatment failed to exert
its inhibitory effects on the modulation of HBV replication in
1.3NEpm cells (Fig. 3C). Taken together, our data suggests that
The Suppression of HBV Replication by TGF-b1
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the inhibitory effects of TGF-b1 on HBV replication.
TGF-b1 suppresses HBV replication by manipulating
HNF-4a expression
We have provided evidence that the intact HNF4BEs within the
HBV core promoter play an important role in TGF-b1-mediated
antiviral activity. The subsequent question of interest is how TGF-
b1 manipulates the binding of HNF-4a to the HBV core
promoter. To confirm whether TGF-b1 treatment interferes with
the interaction between HNF-4a and its responsive element, the
binding activity of endogenous HNF-4a in the presence or absence
of TGF-b1 was examined by EMSA analysis (Fig. 4A). An EMSA
probe corresponding to the 59-HNF4BE located within HBV core
Figure 3. The HNF-4a binding sites within the HBV core promoter are essential elements for the TGF-b1-mediated suppression. (A)
Schematic illustration of HBV-expressing plasmids with HNF-4a binding sites mutations within the HBV core promoter region. (B) Stably HBV-
producing cell lines (1.3ES2 and 1.3NEpm) were treated with or without TGF-b1 for 6 days. To determine the expression level of HBc, cell lysate was
extracted and subjected to Western blot analysis. The loaded amount of total protein was adjusted by the expression level of actin. (C) Total DNA was
extracted from stable HBV-producing cell lines followed by HindIII digestion, and the viral replicative intermediates were examined by Southern blot
analysis using an HBV-specific probe. The integrated HBV genomes were revealed as the internal control for equal amount of sample loading. Bands
corresponding to the integrated genome (integrated), the relaxed circular double-stranded DNA (RC), the replicative intermediates are indicated
individually.
doi:10.1371/journal.pone.0030360.g003
Figure 2. The HNF-4a binding sites within HBV core promoter are the essential elements for the inhibitory effects of TGF-b1. For the
promoter activity assay, HepG2 cells were transfected with luciferase reporter plasmids driven by HBV core promoter (CP) and enhancer I/X promoter
(EnI/X) (A), with luciferase reporter plasmids driven by HBV core promoter (CP) and truncated HBV core promoters (CPD1, CPD2 and CPD3) (B), or with
luciferase reporters with HNF4BE(s)-mutated HBV core promoters (NEm, Npm and NEpm) (C). Two days after TGF-b1 treatment, the cell lysate was
extracted for luciferase activity analysis. The luciferase activities from cells transfected with different reporter plasmids were normalized to the
galactosidase activities from co-transfected pCMV-beta-galactosidase plasmids, and the relative luciferase activities were compared to that of core
promoter (CP) or enhancer I/X promoter (EnI/X), respectively. The relative ratio of their promoter activities between TGF-b1-treated cells and
corresponding mock control cells were shown below. The schematic illustration shows the reporter constructs with deletions or specific mutations of
HNF-4a binding sites in the HBV core promoter region. The results were shown as relative ratio of the firefly luciferase activities normalized to the
beta-galactosidase activities in triplicates (mean value6S.D). Statistical analyses were carried out by 2-sided paired t test, and the star symbol
representing the p values less than 0.01 were considered as statistically significant.
doi:10.1371/journal.pone.0030360.g002
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activity of endogenous HNF-4a to its responsive probe was
significantly reduced after TGF-b1 treatment (Fig. 4A). We next
investigated whether TGF-b1 affects the expression of HNF-4a in
1.3ES2 cells. Surprisingly, we found that TGF-b1 treatment
resulted in a dramatic reduction in HNF-4a mRNA (Fig. 4B).
Furthermore, a significant disappearance of HNF-4a protein by
TGF-b1 treatment was observed by Western blot analysis (Fig. 4C).
HNF-4a plays a crucial role in the suppressive effect of
TGF-b1 on HBV replication
To confirm the significance of HNF-4a protein in mediating the
antiviral effect of TGF-b1, the expression level of endogenous
HNF-4a was specifically reduced by RNA interference (RNAi)
technique, and then the inhibitory effects of TGF-b1 were
analyzed. Consistent with the previous study [27], the reduction
of HNF-4a expression by RNAi was sufficient to trigger HBc
Figure 4. TGF-b1 treatment represses HNF-4a expression in HBV-producing cells. (A) The binding activity of endogenous HNF-4a in the
presence or absence of TGF-b1 was examined by EMSA analysis. Nuclear extracts were prepared from HepG2 cells with or without TGF-b1 treatment
for 2 days, and then incubated with HBV-specific probes containing HNF-4a binding element. Lane 1 is a free probe control without any nuclear
extracts. Lane 2 is the specific probe incubated with HepG2 nuclear extracts. Lane 3 is the specific probe incubated with TGF-b1-treated nuclear
extracts. Lane 4 is the specific probe incubated with HepG2 nuclear extracts and antibody against HNF-4a. Lane 5 is the specific probe incubated with
HepG2 nuclear extracts and 100-fold molar excess cold competitor. (B) 1.3ES2 cells were plated followed by TGF-b1 treatment for 6 days. Total RNA
was extracted analyzed by Northern blot with an HNF-4a specific probe. The expression of GAPDH was used as loading control. (C) 1.3ES2 cells were
treated with TGF-b1 for 6 days. To examine the expression of HNF-4a, the cell lysate was extracted and subjected by Western blot analysis. The
loaded amount of total protein was adjusted by the expression level of actin. (D) 1.3ES2 cells were infected with lentivirus carrying HNF-4a shRNA.
The transduced cells were selected with puromycin, and then cells were treated by TGF-b1 for 6 days. The cell lysate was collected for Western blot
analysis to determine the expression level of HNF-4a and HBc. The total protein loaded was adjusted by actin expression level.
doi:10.1371/journal.pone.0030360.g004
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TGF-b1 significantly repressed HBc expression in these mock
control cells, the level of TGF-b1-mediated HBc reduction in these
HNF-4a knock-down cells was relatively less significant (Fig. 4D).
Since the metabolism of HNF-4a by TGF-b1 treatment has been
reported to be mediated through the proteasome-dependent
degradation pathway [28], we next examined whether blocking
the TGF-b1-mediated HNF-4a degradation by proteasome
inhibitor MG132 could alter the consequence of HBc suppression
by TGF-b1 treatment. We found that MG132 treatment not only
protected HNF-4a protein from degradation but also prevented
HBc from TGF-b1-mediated repression (Fig. 5A). Interestingly,
Northern blot analysis revealed that the reduction of the 3.5 kb
transcripts by TGF-b1 was also prohibited while cells were
pretreated with MG132 (Fig. 5B). Taken together, our data
indicate that the manipulation of HNF-4a expression plays a
crucial role in diminishing of HBc expression as well as pgRNA
transcription during TGF-b1 treatment.
Figure 5. HNF-4a plays a crucial role in the TGF-b1-associated inhibitory effect on HBV replication. 1.3ES2 cells were treated with or
without 10 mM MG132 for 1 hour and TGF-b1 for 12 hours. (A) The cell lysate was collected for Western blot analysis for the detection of HNF-4a and
HBc. The loading amount of total protein was monitored by actin. (B) Total RNA was extracted, and the expression of HBV transcripts were revealed
by Northern blot with using an HBV-specific probe. The expression of GAPDH was used as the loading control. (C) HepG2 cells were transfected with
pHBV1.3 plasmids and an increased amount of rat HNF-4a-expressing plasmids. After treated with TGF-b1 for 2 days, the cell lysate was collected for
the detection of HNF-4a and HBc by Western blot analysis. The expression of core particles was examined by particle blot analysis. The equal amount
of total protein was revealed by the level of actin. The amount of HBc and HBV particle were also adjusted by the expression level of EGFP for
monitoring the transfection efficiency. (D) Total RNA was extracted, and the expression of HBV transcripts were revealed by Northern blot with an
HBV-specific probe. The expression of the kanamycin-neomycin phosphate transferase (kan/neo) was used as the loading control. Total DNA was
extracted followed by HindIII digestion. The viral replicative intermediates were examined by Southern blot analysis using an HBV-specific probe.
Bands corresponding to the relaxed circular double-stranded DNA (RC), the replicative intermediates are indicated individually.
doi:10.1371/journal.pone.0030360.g005
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can rescue HBV replication
To further confirm that whether the expression level of HNF-4a
is the key parameter in modulating of the HBV replication by
TGF-b1, HBV-producing cells were induced to express different
amounts of rat HNF-4a in the presence of TGF-b1. Our data
revealed that ectopic expression of rat HNF-4a alone was
sufficient to rescue the impaired HBc expression caused by
TGF-b1 treatment (Fig. 5C, Western blot), and that the
assembling of intracellular viral particles could also be restored
by rat HNF-4a overexpression (Fig. 5C, Particle blot). Moreover,
the expression level of HBV transcripts (such as 3.5 kb pre-C
mRNA/pgRNA and 2.4–2.1 kb subgenomic mRNAs) and
intracellular viral replicative intermediates were both elevated in
parallel with the increased amounts of rat HNF4 (Fig. 5D,
Northern blot and Southern blot). In conclusion, we provide
evidence to support our scenario in which the crucial hepatic
transcription factor HNF-4a is indispensable for the suppressive
effect of TGF-b1 on HBV replication.
Discussion
TGF-b1 inhibits HBV replication through the modulation
of HNF-4a
Our results indicate that TGF-b1 exerts its anti-HBV effect
through the modulation of cellular HNF-4a as explained in a
proposed model (Fig. 6). Briefly, the abundantly expressed HNF-
4a is loaded to the HNF4BE(s) within HBV core promoter and
subsequently enhances the transcription of HBV pgRNA. The
pgRNA serves as the mRNA for HBc synthesis, and then these
HBc in turn assemble with pgRNA to form viral particle. In the
presence of TGF-b1, the expression of HNF-4a is diminished.
Lacking of HNF-4a, the HBc synthesis is dramatically reduced,
and subsequently the formation of nucleocapsid as well as HBV
replication is repressed. Our study suggests that liver-enriched
transcription factor HNF-4a plays vital role in HBV suppression
by TGF-b1.
The inhibitory effects of TGF-b1 on the modulation of
HBV transcription
In this report, we continued our previous research on TGF-b1-
mediated HBV repression and explored the mechanism how
TGF-b1 interferes with HBV replication. Our data suggested that
the reduction of cellular HNF-4a by TGF-b1 treatment
dramatically diminishes the expression level of HBV pgRNA,
but not pre-C mRNA. Although the promoter regions of pgRNA
and pre-C mRNA are highly overlapped and share the same
transcription factor binding motifs, it has been indicated that the
transcriptions of the pgRNA and pre-C mRNA are differentially
regulated and are directed by two distinct promoters [8]. The
basal elements of these two promoters are similar but genetically
separable, with each consisting of its own transcriptional initiator
and a TATA box-like sequence [8]. Furthermore, it has been
reported that HNF-4 differentially regulates pgRNA and pre-C
mRNA, of which HNF-4 specifically activates the transcription of
pgRNA, but not pre-C mRNA [8,12]. One possible explanation
was provided by Yu et. al., they found that the 39 HNF-4 binding
element was overlapped with the TATA-box of pre-C promoter,
and the binding of HNF-4 on this region might interfere with the
assembling of the initial transcription complex for pre-C mRNA
production [8]. As a consequence, it is not surprising that the
reduction of HNF-4a by TGF-b1 has more impact on the
suppression of pgRNA than pre-C mRNA.
It has been well demonstrated that HNF-4a binding sites
located within HBV core promoter (enhancer II) region and
enhancer I/X promoter region are critical cis-acting elements for
the regulation of HBV replication [29,30]. However, TGF-b1
differentially regulates HBV core promoter and enhancer I/X
promoter, that is, TGF-b1 significantly inhibited HBV core
promoter but only slightly modulates enhancer I/X promoter. It is
likely due to that HNF-4a has much higher binding affinity for its
responsive element(s) in HBV core promoter (enhancer II) than
that in enhancer I/X promoter [31].
In addition to 3.5 Kb HBV transcripts, we found that the
expressions of 2.1–2.4 Kb HBV subgenomic RNAs were also
repressed by TGF-b1 treatment (Fig. 1B). Several transcription
factors (including HNF1, HNF3, SP1, TBP, CBF, NF-Y and NF1),
but not HNF-4, have been suggested to locate onto HBV surface
promoter and regulate the expression of these HBV subgenomic
RNAs [4]. Among them, the expression of HNF-3b has been
proved to substantially increase the transcriptional activity of
surface promoter [32]. Interestingly, our preliminary data showed
that the reduction of 2.1–2.4 Kb HBV transcripts were in parallel
with the repression of HNF-3b expression during TGF-b1
treatment (data not shown). Considering the hierarchical role of
HNF-4a, it raised the possibility that the changes in HNF-4a
expression level might lead to the alteration of HNF-3b
expression. This idea is supported by our previous research in
which we demonstrated that overexpression of HNF-4a signifi-
cantly upregulates the transcription of HNF-3b [33]. Moreover,
we showed that overexpression of HNF-4a could rescue the
expression of 2.1–2.4 Kb HBV transcripts under TGF-b1
treatment (Fig. 5D). Taken together, we believe that TGF-b1
might indirectly repressed HNF-3b expression, probably through
reducing of HNF-4a expression, and consequently inhibited the
expression of these HBV subgenomic RNAs.
The role of HNF-4a in cytokine-mediated HBV clearance
The time course studies of viral DNA disappearance and T cells
infiltration suggested that HBV clearance occurs before the
destruction of infected hepatocytes [34], which indicates that
cytokine-mediated non-cytopathic viral clearance plays an impor-
tant role in the inhibition of HBV replication. Several cytokines
including interleukin-4 (IL-4), IL-6, IL-18, interferons (IFNs),
tumor necrosis factor-alpha (TNF-a) and TGF-b1 were demon-
strated to effectively and noncytopathically suppress HBV
replication [23,35,36,37,38,39,40]. Among them, TGF-b1 is the
only cytokine reported to efficiently suppress HBV replication at a
physiological concentration. In this report, we continue our
previous study and clarify the detail mechanism by which TGF-
b1 inhibits HBV replication. We found that TGF-b1 represses
HBV replication primarily through the specifically inhibiting of
viral core protein expression. This inhibitory effect triggered by
TGF-b1 is similar to that caused by IL-4, IL-6, IFN-a, IFN-c,o r
TNF-a, all of which have been reported to reduce HBV core
protein level [38,39,40,41]. However, the molecular mechanisms
by which these cytokines exert their inhibitory effects on the core
promoter are not well investigated. Here, we suggested that HNF-
4a plays a crucial role in TGF-b1-mediated suppression of the
HBV core promoter, which subsequently blocks HBc synthesis
and HBV replication. Previous study of HBV infection in primary
human liver cells suggested that Kupffer cells can secrete IL-6
upon viral recognition, and in turn inhibits HBV replication by
downregulation of HNF-1a and HNF-4a [40]. Moreover, the
study of a natural helioxanthin analogue showed that the main
antiviral mechanism triggered by this compound is also mediated
by downregulation of HNF-3 and HNF-4a [42]. Meanwhile,
The Suppression of HBV Replication by TGF-b1
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30360Figure 6. Schematic illustration of our model in which TGF-b1 exerts its anti-HBV effect through the modulation of cellular HNF-4a
expression level. In the hepatocytes, the abundantly expressed HNF-4a efficiently activates the transcription of HBV pgRNA. The accumulated
pgRNA not only serve as the templates for synthesis of viral core protein but also assemble with HBV core protein to form viral nucleocapsids. In TGF-
b1-treated hepatocytes, the expression level of HNF-4a is dramatically reduced, which severely interfere with the synthesis of pgRNA and HBV core
protein. Lacking of those viral components, the formation of nucleocapsid and HBV replication are substantially suppressed.
doi:10.1371/journal.pone.0030360.g006
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medicine Xiao-Chai-Hu-Tang, was suggested to suppress HBV
production by compromising the binding between HNF-4a and
HBV core promoter [43]. In conclusion, HNF-4a is certainly one
of the critical targets involved in viral clearance during the
modulation of HBV replication.
Down-regulation of HNF-4a by TGF-b1 treatment
The repression of HNF-4a expression by TGF-b1 has been
reported to be exerted through several distinct mechanisms
[28,44,45]. For example, TGF-b1 induced the expression of
transcription repressor Snail in hepatocytes, which in turn reduced
the transcription of HNF-4a gene through direct binding of Snail
within the HNF-4a promoter region [44]. In addition, another
transcription repressor HMGA2 was activated through TGF-b1-
induced Smad3 signaling pathway in mammary epithelial cells
and subsequently suppressed the transcription of HNF-4a [45].
Moreover, TGF-b1 induces the elevation of miR-24 expression
[46], which in turn targets to the 39-UTR of HNF-4a and
regulates the level of HNF-4a by a post-transcriptional control
[47]. It is also suggested that the post-translational modification is
involved in the suppression of HNF-4a activity, in which the
phosphorylated HNF-4a prevents protein dimer formation and
affects its own protein stability [48]. Besides, IL-1b and TGF-b1
are both reported to induce HNF-4a degradation via the
proteasome dependant pathway, and the reduction of HNF-4a
could be rescued by the addition of the proteasome inhibitor,
MG132 [28,49]. In our study, the transcriptional repression of
HNF-4a was observed in the presence of TGF-b1 (Fig. 4B).
Furthermore, we also observed that HNF-4a protein was
repressed after TGF-b1 treatment (Fig. 4C), and the TGF-b1-
induced HNF-4a degradation was prevented by the pretreatment
of MG132 (Fig. 5A). A putative PEST signal has been predicted
near the C-terminus of HNF-4a amino acid sequence [49], which
might be responsible for the target of HNF-4a to rapid destruction
and confer its instability after TGF-b1 treatment [50].
HNF-4a plays a hierarchical role in hepatocyte
differentiation and controls viral replication
HBVreplicationisnotonlyregulatedbytheexpressionofhepatic
transcription factors [25], but is also closely related to the
differentiation status of hepatocytes [51]. Several lines of evidence
suggest that modulating the expression of hepatic transcription
factors is tightly linked to hepatocyte differentiation status. For
example, the differentiated primary hepatocytes induced by
dimethyl sulfoxide treatment reveal higher levels of HNF-1a,
HNF-1b, HNF-3c, and HNF-4a than proliferating cells [52]. A
complicated cross-regulatory network betweenhepatictranscription
factors has been constructed by analyzing the expression levels of
transcription factors in developing liver [53]. Within this network, a
core group of six hepatic transcription factors (HNF-1a, HNF-1b,
HNF-3b, HNF-4a, HNF-6, and liver receptor homolog-1) are
suggested to regulate with each other and the downstream hepatic
regulators [53]. Of these, HNF-4a has been identified as the central
regulator of multiple genes contributing to hepatocyte differentia-
tion, including HNF-1a and pregnane X receptor [14,54]. In this
report, we demonstrated that TGF-b1 strongly represses the
expression of HNF-4a, which raises the possibility that the loss of
HNF-4a might consequently affect the differentiation status of
hepatocytes. In addition to HNF-4a, we observed a significant
reduction in the binding activity of HNF-1 and HNF-3 in our
EMSA analysis after TGF-b1 treatment (data not shown). We also
found that the expression level of HNF-1 and albumin were down-
regulated by TGF-b1 treatment (data not shown). These findings
imply that TGF-b1 is able to alter the expression of several
transcription factors and the differentiation status of hepatocytes.
Thus,wesuggestedthat TGF-b1 diminishes the expressionofHNF-
4a, which may regulate HBV replication not only by directly
reducing HBV core protein biosynthesis but also by indirectly
affecting other hepatic genes and hepatocyte differentiation status.
The immunosuppressive roles of TGF-b1 in HBV infection
It is well established that TGF-b1 functions as a negative
regulator of cellular and humoral immune responses during HBV
infection, including lymphocyte proliferation, IFN-c secretion, and
antibody production [55]. Recently, studies in chronically HBV-
infected patients revealed that the elevation of serum TGF-b1i s
accompaniedbyanincreasedfrequencyofregulatoryT cells(Tregs)
[56]. Moreover, it has been well demonstrated that TGF-b1
converts native T cells into Trgs in the periphery [57]. It provides
new insight into the immunosuppressive role of TGF-b1 in viral
hepatitis. Growing evidence suggests that Tregs control the immune
responses to hepatitis viruses by modulating effector T cell
activation [58,59]. During chronic virus infection, Tregs appear
to restrain overactive immune responses and eliminate host tissue
damage [60]. Furthermore, increased numbers of cytotoxic T
lymphocyte are observed after the Tregs decline, supporting a role
for Tregs in controlling immune responses during HBV infection
[61]. In this study, we have shown clearly that TGF-b1 can
efficiently repress HBV replication by impairing HNF-4a expres-
sion, which likely contributes to the restriction of virus replication
during HBV infection. Taken together, all the evidence suggests
that the elevated TGF-b1 in chronically HBV-infected patients
might have dual biological significance, both reducing viral DNA
load and preventing liver damage during persistent HBV infection.
With virus-suppressing and immune-restraining features, we believe
that TGF-b1 might play a unique role in cytokine-mediated HBV
clearance. However, the possible therapeutic applications of TGF-
b1 in HBV patients need to be further investigated.
Materials and Methods
Cell Culture and Transfection
The stable HBV-producing cell line, 1.3ES2 cells, is a clone
derivative of HepG2 cells in which the 1.3 copies of the entire
HBV genome was stably integrated [62]. Human hepatoblastoma
cell line, HepG2 cells, and the stably HBV-producing cell line,
1.3ES2 cells, were maintained as previously described [23].
HepG2 cells were transfected with HBV-expressing plasmids or
reporter plasmids by using Arrest-In transfection reagent (Thermo
Scientific, Waltham, MA). HNF4BEs-mutated HBV-producing
cell line, 1.3NEpm, was established by transfected with HBV
HNF4BEs-mutated plasmid and selected with hygromycin. To
assess the antiviral effect of TGF-b1 on HBV replication, cells
were treated with 10 ng/ml or 20 ng/ml of TGF-b1 (R&D
Systems, Minneapolis, MN).
Plasmid Construction
To analyze HBV core promoter activity, several reporter
plasmids were constructed with the luciferase gene under the
control of distinct core promoter regions and were transfected into
HepG2 cells to analyze their luciferase activity. The HBV core
promoter (CP: nucleotides 1636–1851) was amplified from the
ayw subtype of the HBV genome [63] and was subcloned between
MluI and HindIII restriction sites on the pGL3-Basic luciferase
vector (Promega Corporation, Madison, WI). Reporters with with
the HBV enhancer I/X promoter (EnI/X: nucleotides 947–1372)
and HBV core promoter deletions (CPD1: nucleotides 1656–1851,
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1851) were also constructed by the same strategy. HNF4BE
mutants were generated using the QuikChange II Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) to alter the parental
HNF-4a binding sequences in either the HBV core promoter
reporter or HBV-expressing plasmids (pHBV1.3), which was
constructed as previously described [62]. The mutant of the 59-
HNF4BE (NEm) was constructed by substituting the wild-type
HNF4BE (GGACTCTTGGACTC) with a mutant 59-HNF4BE
(GcACTCTTcGACTC), which was not bound by HNF-4a [12].
The mutant 39-HNF4BE (Npm) was generated by replacing the
wild-type 39-HNF4BE (AGGTTAAAGGTCT) with the mutant
39-HNF4BE (AGaTTAAAaGTgT), which impaired the interac-
tion with HNF-4a [26]. The construct with mutations at both 59-
and 39-HNF4BEs was named as NEpm. In this report, the unique
EcoRI recognition site within the HBV genome is defined as
nucleotide 1.
Northern Blot Analysis
Total RNA was isolated using TRIzol solution (Invitrogen,
Carlsbad, CA) and was separated on a 1.2% formaldehyde-agarose
gel and transferred onto positively charged Hybond-N+ nylon
membranes (GE Healthcare, Piscataway, NJ). The membranes were
UV cross-linked and hybridized with
32P-labeled HBV-specific or
HNF-4a-specific probes, which were generated by a Prime-a-Gene
Labeling System(Promega Corporation,Madison, WI).The loading
amount of total RNA was monitored using a GAPDH-specific
probe. The isotope signals were detected with a phosphoimager
FLA-2000 image system (Fujifilm, Minato-ku, Tokyo, Japan).
Primer Extension Analysis
Total RNA was isolated, and the same amount total RNA was
applied for the relative quantitation of HBV pregenomic RNA
(pgRNA) and pre-C mRNA as previously described by Ou et al.
[64]. The abundance of pre-C mRNA and pgRNA was detected
by a
32P-labeled 28-mer primer corresponding to HBV nucleotides
2051–2024 [64].
Western Blot Analysis
Total protein was separated by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred
onto polyvinylidene fluoride membranes (Millipore, Billerica, MA).
The membranes were blocked with 5% nonfat milk and incubated
with HBc-specific or HNF-4a-specific antibodies. The immunoblot
signals were examined using enhanced chemiluminescence reagent
(Millipore, Billerica, MA) and detected with a UVP BioSpectrum
500 image system (UVP, Upland, CA). Antibody against HBc was
purchased from Dako (Carpinteria, CA), anti-HNF-4a antibody
from Santa Cruz Biotechnology (Santa Cruz, CA), anti-actin
antibody from Millipore (Millipore, Billerica, MA) and anti-EGFP
antibody from Clontech (Clontech, Mountain View, CA).
Particle Blot Analysis
Analysis of intracellular HBV core particles was performed as
previously described [65,66]. In brief, cell lysate was separated on a
1.2% native agarose gel and transferred onto polyvinylidene fluoride
membranes or nylon membranes for the detection of HBV core
particles. HBV core particles were examined by immunoblot
analysis using an anti-HBc antibody. Capsid-associated nucleic acids
were released from the core particles in situ by denaturing the
membranes with 0.2 N NaOH/1.5 M NaCl, and neutralizing with
0.2 N Tris-HCl/1.5 M NaCl. Finally, the membranes were
hybridized with an HBV-specific probe as previously described [23].
Luciferase Assay
To analyze the activities of HBV core promoters, HepG2 cells
were transfected with each reporter construct and CMV promoter-
driven beta-galactosidase plasmid for monitoring the transfection
efficiency. One day after cotransfection, cells were treated with or
without TGF-b1 (10 ng/ml) for two days. Luciferase and beta-
galactosidase activities were quantified with Bright Glo luciferase
assay kits (Promega Corporation, Madison, WI) and Beta Glo
luciferase assay kits (Promega Corporation, Madison, WI), respec-
tively. The luciferase signals were determined using a Hidex
Chameleon luminescence reader (Hidex, Turku, Finland).
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was performed as previously described by Niehof et al.
[67]. In brief, nuclear extracts were prepared from HepG2 cells
treated with or without TGF-b1 for two days by nuclear and
cytoplasmic extraction reagents NE-PER (Thermo Scientific,
Waltham, MA). The oligonucleotides were purchased with the
following sequences: AGAGGACTCTTGGACTCTCAGCA and
TGCTGAGAGTCCAAGAGTCCTCTT, annealed, and 59-end-
labeled with
32P by T4 polynucleotide kinase (Promega Corpo-
ration, Madison, WI). The oligonucleotide were then extracted by
phenol/chloroform and purified by Sephadex G-25 column (GE
Healthcare, Piscataway, NJ). Super shift assays were done with
HNF-4a specific antibody (sc-6556) was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). For competition EMSA,
100 fold excess cold oligonucleotides were used.
RNA Interference
Lentivirus carrying HNF-4a-specific short hairpin (sh)RNA
(purchased from the National RNAi Core Facility, Taiwan) was
used to knock down endogenous HNF-4a. The target sequence
within the HNF-4a gene was CGAGCAGATCCAGTTCAT-
CAA. Stably HBV-producing 1.3ES2 cells were spin infected with
lentivirus in 8 mg/ml polybrene at 1,1006 g for 30 min
(multiplicity of infection=2), and the media was refreshed one
day after the infection. The lentivirus-infected 1.3ES2 cells were
then selected with 2 mg/ml of puromycin for two days and
followed by TGF-b1 treatment as described above.
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